IPP Bureau
Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development
By IPP Bureau - June 23, 2026
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
KIMS Hospitals launches RENOVA Oncology Institute in Bengaluru
By IPP Bureau - June 23, 2026
KIMS RENOVA Oncology Institute, in association with the Samrohana Cancer Foundation, announced the “134 Free Screening Camp Pledge”,
Teva submits FDA application for experimental Tourette syndrome treatment ecopipam
By IPP Bureau - June 23, 2026
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
FDA advisory panel backs Moderna flu vaccine candidate for older adults
By IPP Bureau - June 23, 2026
The backing comes as influenza remains a persistent public health burden
FDA clears 131 drugs as global pharma approval momentum rebounds in 2025
By IPP Bureau - June 23, 2026
After a volatile decade in which approvals swung sharply from year to year, 2025’s total pushed past long-term norms, exceeding the 10-year average
Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results
By IPP Bureau - June 23, 2026
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
WuXi Biologics wins fourth EMA certification for Suzhou Biosafety Center
By IPP Bureau - June 23, 2026
Clearing 19 biologics for Europe market
ZEISS and Envision Health Technologies team up to push VR-based glaucoma testing forward
By IPP Bureau - June 23, 2026
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
Biopharma funding rebounds in 2026, but capital flows to lower-risk assets
By IPP Bureau - June 22, 2026
M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Saurabh Gambhir elevated to Chief Strategy Officer (Global) at Cipla
By IPP Bureau - June 22, 2026
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
MICK Digital empanelled as AMTZ authorized channel partner
By IPP Bureau - June 22, 2026
Partnership strengthens healthcare technology distribution capabilities, enabling wider reach of Make-in-India medical devices through government and institutional healthcare networks
BPL Medical honours strategic partners with Pinnacle Awards 2026
By IPP Bureau - June 22, 2026
The company hosted Symbiosis 2026 at its 2-acre manufacturing facility in Bengaluru, inaugurated in 2024
Aurobindo Pharma USA secures FTC clearance for $250 million Lannett acquisition
By IPP Bureau - June 22, 2026
Through the transaction, Aurobindo USA will expand its product portfolio in this segment while gaining a U.S.-based manufacturing facility
CENT expands to Delhi-NCR with new clinical prevention centre in Gurugram
By IPP Bureau - June 22, 2026
New Gurugram centre is India's first clinical Prevention Centre with 2 state of the art MRI machines and a capacity of 2000 scans a month
Nearly half of cardiac investigations in men above 30 show abnormalities, claims report
By IPP Bureau - June 22, 2026
Study of 78,000 diagnostic investigations by Mahajan Imaging identifies over 13,000 abnormal or critical findings, highlighting silent health risks among working-age men
